Though warranted in HNSCC in general, careful patient selection or retrospective analysis may be necessary, as HPV+, mTOR activated, or therapy resistant recurrent/metastatic disease may be of greatest benefit. This evidence concerns the gene MTOR and head and neck squamous cell carcinoma.